Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 8.01 (Other Events). FDA partial clinical hold pauses new BHV-7000 enrollment after insufficient metabolite safety information from rodent testing.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA partial clinical hold pauses new BHV-7000 enrollment after insufficient metabolite safety information from rodent testing
- Dosing continues for more than 600 randomized patients, including fully enrolled BHV7000-303
- BHV7000-303 topline readout remains scheduled for the second half of 2026
- BHV7000-302 and global sites face enrollment pauses pending additional nonclinical data expected in coming weeks
- SK Biopharmaceuticals license covers worldwide Kv7 platform, including BHV-7000, with closing dependent on HSR submission
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.